Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
about
Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves[Drug induced QT prolongation].Antiarrhythmic drugs for atrial fibrillation.What niche will newer class III antiarrhythmic drugs occupy?Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation.Advances in the acute pharmacologic management of cardiac arrhythmias.Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.Amiodarone: a multifaceted antiarrhythmic drug.Drug-induced QT-interval prolongation: considerations for clinicians.Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion.Characterization of transient atrial rhythm occurring between typical atrial flutter and its termination with class III drugs.Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone.Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter.Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.The safety and efficacy of ibutilide in children and in patients with congenital heart disease.The Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation (MAGIC-AF) Study: clinical background and study design.
P2860
Q24601144-7C0DC260-C0F8-4DBB-B146-33FD0A5834F5Q33156106-29E7C069-4B73-46EA-BC8D-64638A81B2A5Q33821199-A9F0DDC7-9C63-4C23-BCCB-CE80765AA2DFQ34282152-3041B857-1795-4321-A36A-6A7CE7054AC5Q34422636-E92039EE-A3F5-4B95-BD1D-8E7A2644AC45Q35198974-76446888-AA12-44F2-AA8E-7DA9A07BA190Q35771784-C7CB7591-E713-4993-AADE-C7FFD54AA3A2Q35892164-0BFC6670-0341-48C5-85C4-D9883470A347Q35892167-796FD79C-563C-4867-B6FD-12618A3442BEQ36586992-E9B8BB89-4B1E-4928-8589-EA7EB8539402Q37767425-163EEF5E-3A4A-40CA-8E2A-B6943CF2ECA3Q44136941-FB04AABD-555D-4761-9692-5991CE1C0A3CQ46442766-62DD41C7-9539-4E7E-857D-88F264C0ADC9Q46714769-FAEB1073-5E85-4002-81AD-4F25FFAFE601Q46919952-73EF44AF-4D64-44BF-BCAF-089CD4B0DADCQ46980852-69EC597C-F282-4AC8-A1AB-5962CC054F26Q50946342-4A07CE99-6E52-4812-BA00-DBC0AB80A341Q53194476-8ED80956-5AF0-44F6-A729-F9CAD3EB9698
P2860
Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chemical cardioversion of atri ...... receiving amiodarone therapy.
@ast
Chemical cardioversion of atri ...... receiving amiodarone therapy.
@en
type
label
Chemical cardioversion of atri ...... receiving amiodarone therapy.
@ast
Chemical cardioversion of atri ...... receiving amiodarone therapy.
@en
prefLabel
Chemical cardioversion of atri ...... receiving amiodarone therapy.
@ast
Chemical cardioversion of atri ...... receiving amiodarone therapy.
@en
P2093
P356
P1433
P1476
Chemical cardioversion of atri ...... receiving amiodarone therapy.
@en
P2093
Chatterjee K
Scheinman MM
P304
P356
10.1161/01.CIR.103.2.253
P407
P577
2001-01-01T00:00:00Z